Verona Pharma (VRNA) Set to Announce Quarterly Earnings on Thursday

Verona Pharma (NASDAQ:VRNA) will issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA) last issued its earnings results on Thursday, February 29th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. On average, analysts expect Verona Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verona Pharma Trading Down 1.1 %

Shares of NASDAQ VRNA opened at $14.79 on Wednesday. The firm has a market cap of $1.20 billion, a PE ratio of -21.43 and a beta of 0.43. The company has a quick ratio of 33.33, a current ratio of 33.33 and a debt-to-equity ratio of 0.20. Verona Pharma has a twelve month low of $11.83 and a twelve month high of $23.81. The business has a fifty day simple moving average of $16.09 and a two-hundred day simple moving average of $16.21.

Insiders Place Their Bets

In other Verona Pharma news, insider Kathleen A. Rickard sold 36,248 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $1.96, for a total transaction of $71,046.08. Following the completion of the sale, the insider now owns 2,621,552 shares of the company’s stock, valued at $5,138,241.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on VRNA. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Verona Pharma in a research note on Friday, March 1st. Piper Sandler raised their target price on Verona Pharma from $31.00 to $36.00 and gave the company an “overweight” rating in a research report on Tuesday, April 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Verona Pharma in a report on Monday, March 4th. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Verona Pharma has a consensus rating of “Buy” and a consensus price target of $33.60.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.